Notice of Winter Holidays

Mediplus Pharmaceuticals Co., Ltd. will be closed for winter holidays from Thursday, December 28, 2024, to Sunday, January 5, 2025.

During this period, we will continue to receive inquiries via fax and email; however, please note that we will not be responding to inquiries or processing orders until we resume operations.

We apologize for any inconvenience this may cause and appreciate your understanding.

We presented and exhibited at the 67th Annual Conference of Comparative Integrative Medicine.

The conference was held on November 30 and December 1, 2024. Our Executive Fellow, Mr. Shioda, delivered a presentation titled “A Study of 34 Cases of Skin and Oral Diseases in Dogs and Cats Using Ozone Glycerin Formulation”.

On the same day, we also participated in the exhibition booth at the conference, promoting our ozone glycerin formulation.

Presentation at the 29th Annual Meeting of the Japanese Society of Clinical Hair Science

Our Executive Fellow, Mr. Shiota, presented on the topic “Efficacy Evaluation of Ozonated Glycerin Formulations for Hair” at the 29th Annual Meeting of the Japanese Society of Clinical Hair Restoration, held on November 2-3, 2024.

Presentation of Clinical Cases Using Our Product at the 10th Annual Meeting of the Japanese Veterinary Homeopathy Association


On October 13, 2024, at the 10th Annual Meeting of the Japanese Veterinary Homeopathy Association, we presented clinical cases using our product, OGS Paste (tentative), during the corporate briefing session. We are committed to contributing to the advancement of veterinary medicine through continued innovation and product development.

Our Director’s Interview Featured in WWD BEAUTY JAPAN

In the August 26, 2024 issue of WWD BEAUTY(published by WWD JAPAN) an interview with our Director and Executive Fellow, Gotaro Shioda, was featured under the title “The Potential of ‘Ozonized Glycerin’ for Dramatic Skin Regeneration Without Side Effects” in the article “BEAUTY RESEARCHERS Vol.8”.

Read more

Exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI)

On Sunday, July 7, 2024, we exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI), a non-profit organization (NPO) event held in Fukuoka City.

Read more

Presentation on the efficacy of Ozonized Glycerin (Novel Glycerin Compound) formulation for Atopic Dermatitis at the Japanese Dermatological Association

Mediplus Pharma, Inc. presented the safety and efficacy of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), in formulations for atopic dermatitis at the 123rd Annual Meeting of the Japanese Dermatological Association. The conference was held from June 6 to June 9, 2024, at the Kyoto International Conference Center.

For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000015.000079724.html

World Biomaterials Congress

Presentation on Multifunctionality of Ozonized Glycerin (Novel Glycerin Compounds) and Their Application as Biomaterials at the World Biomaterials Congress

Mediplus Pharma, Inc. (CEO: Kenji Ito, HQ: Shibuya, Tokyo) presented on the multifunctionality and application of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), as biomaterials at the 12th World Biomaterials Congress (WBC), held over six days from May 26 to 31, 2024, in Daegu, South Korea.

For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000013.000079724.html

Announcement of Exhibition at the Institute for Predictable Osseointegration in Implantology Academic Conference

We are pleased to announce our participation in the 16th Academic Conference of the Non-Profit Organization (NPO) Institute for Predictable Osseointegration in Implantology, which will be held on Sunday, July 7, 2024, in Fukuoka City.
We aim to introduce our unique ingredient , ozonized glycerin, which is expected to have beneficial effects in dental medicine, particularly in the surgical field. This event will be an opportunity for dental professionals, especially those active in the surgical domain, to learn about our product.
At our exhibition booth, attendees will be able to experience ozonized glycerin and deepen their understanding through explanations from the developers.

Presentation on the Efficacy of Novel Glycerin Compounds for Atopic Dermatitis at AAD

A presentation on the safety and efficacy evaluation of atopic dermatitis was held at the American Academy of Dermatology (AAD) in March, and it has been featured in the “Health Industry Distribution Newspaper” issue 1111 (published on 4/25).

We plan to continue utilizing Novel Glycerin Compounds (ozonized glycerin) extensively in the business ventures undertaken by our group companies in the future.

For the AAD presentation release, please visit: